doi: 10.4161/cc.5.3.2393.
Epub 2006 Mar 8.
Implications of the expression of myeloid markers on normal and leukemic stem cells
Affiliations
- PMID: 16397415
- DOI: 10.4161/cc.5.3.2393
Item in Clipboard
Implications of the expression of myeloid markers on normal and leukemic stem cells
Cell Cycle.
2006 Feb.
Abstract
We have recently described the expression of CD33 and other antigens previously thought to be myeloid specific on both acute myeloid leukemia-initiating cells (AML-IC) and normal hematopoietic stem cells (HSC) that are capable of repopulating immuno-deficient mice. Here, we discuss that the presence of myeloid markers on AML-ICs and HSCs makes identification of an antigen for targeted therapy extremely difficult. Xenotransplantation assays should be used wherever possible to test the suitability of candidate antigens for targeted therapy, including the assessment of the effect on normal cells.
Similar articles
-
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.Haematologica. 2012 Feb;97(2):219-26. doi: 10.3324/haematol.2010.035006. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993666 Free PMC article.
-
Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.Leuk Res. 2008 Aug;32(8):1321-2. doi: 10.1016/j.leukres.2007.09.009. Epub 2007 Oct 29. Leuk Res. 2008. PMID: 18029013
-
[Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].Gan To Kagaku Ryoho. 2007 Nov;34(11):1881-3. Gan To Kagaku Ryoho. 2007. PMID: 18030030 Japanese.
-
Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.Leukemia. 2000 Mar;14(3):474-5. doi: 10.1038/sj.leu.2401663. Leukemia. 2000. PMID: 10720144 Review.
-
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.Blood. 2012 Jun 28;119(26):6198-208. doi: 10.1182/blood-2011-11-325050. Epub 2012 Jan 27. Blood. 2012. PMID: 22286199 Free PMC article. Review.
Cited by
-
LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.Mol Cancer Ther. 2020 Nov;19(11):2330-2339. doi: 10.1158/1535-7163.MCT-20-0407. Epub 2020 Sep 2. Mol Cancer Ther. 2020. PMID: 32879051 Free PMC article.
-
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets.Expert Opin Investig Drugs. 2023 Feb;32(2):107-125. doi: 10.1080/13543784.2023.2179482. Epub 2023 Feb 26. Expert Opin Investig Drugs. 2023. PMID: 36762937 Free PMC article. Review.
-
Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.Blood Cancer J. 2011 Sep;1(9):e36. doi: 10.1038/bcj.2011.35. Epub 2011 Sep 30. Blood Cancer J. 2011. PMID: 22829197 Free PMC article.
-
Acute myeloid leukemia stem cells: seek and destroy.Expert Rev Hematol. 2009 Dec;2(6):663-72. doi: 10.1586/ehm.09.53. Expert Rev Hematol. 2009. PMID: 21082958 Free PMC article. Review.
-
3D Multicellular Spheroid for the Study of Human Hematopoietic Stem Cells: Synergistic Effect Between Oxygen Levels, Mesenchymal Stromal Cells and Endothelial Cells.J Blood Med. 2021 Jun 30;12:517-528. doi: 10.2147/JBM.S305319. eCollection 2021. J Blood Med. 2021. PMID: 34234608 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
